Atlanta, April 26 (RHC)-- In the U.S., many states resumed administering Johnson & Johnson’s COVID-19 vaccine over the weekend, after the Centers for Disease Control and Prevention and the Food and Drug Administration ended an 11-day pause on its use. 

Researchers were investigating the vaccine’s link to an extremely rare blood-clotting condition.  Janet Woodcock, acting FDA commissioner, told reporters: "Together, both agencies have full confidence that this vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.”

Federal officials said patients — particularly women under the age of 50 — should be given a warning about the vaccine.  

Over one-third of U.S. adults are now fully vaccinated, with over 50% partially vaccinated, but the rate of vaccination has slowed down over the past week.  Some states are turning down or reducing new vaccine shipments as supply has started to outpace demand.  There is now a growing number of people who are not taking the second vaccine.